Amir Abdoli

Dr. Amir Abdoli

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GCGlobal Burden of Disease Cancer Collaboration
Global Burden of Disease Cancer Collaboration
CFChristina Fitzmaurice
Christina Fitzmaurice
DADegu Abate
Degu Abate
NANaghmeh Abbasi
Naghmeh Abbasi
HAHedayat Abbastabar
Hedayat Abbastabar
CMChristopher J. L. Murray
Christopher J. L. Murray
Cancer is now widely recognized as a global problem that unfortunately lacks a global solution. The latest United Nations high-level meeting on noncommunicable diseases (NCDs) exemplified this conundrum.1 Despite global commitment to reducing the risk of and disability from NCDs, including cancer, implementation of known solutions is inadequate to reach the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases2,3 (25% reduction in premature mortality from NCDs by 2025) and the third Sustainable Development Goal (by 2030 reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and well-being).4 To reduce cancer burden, identifying the scope of the problem and mapping out implementation of solutions is best done in National Cancer Control Plans (NCCPs). However, a recent review showed that only 29% of low-income countries had a NCCP, and even if NCCPs existed, cost, financing, monitoring, and expansion of information systems was often inadequate. Many highly effective prevention and treatment strategies exist for cancer. However, they are often very specific (eg, vaccination for human papillomavirus and hepatitis B virus for prevention of cervical and liver cancer, or tyrosine kinase inhibitors for cancers with targetable mutations). Effective NCCPs therefore require detailed knowledge about the local burden of cancer and associated risk factors. We herein present results from the Global Burden of Disease (GBD) 2017 study describing cancer incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 195 countries from 1990 through 2017, which can inform cancer control through policy, resource allocation, and health system planning.

17 August 2016 in Pathogens and Global Health
Verified
Journal Article
Closed access
NMNahid Maspi
Nahid Maspi
AAAmir Abdoli
Amir Abdoli
FGFathemeh Ghaffarifar
Fathemeh Ghaffarifar
Cutaneous leishmaniasis (CL) is caused by different species of the genus Leishmania. Pro- and anti-inflammatory cytokines play different roles in resistance/susceptibility and the immunopathogenesis of Leishmania infection. The balance and dynamic changes in cytokines may control or predict clinical outcome. T helper 1 (Th1) inflammatory cytokines (especially interferon-γ, tumor necrosis factor-α and interleukin-12) are the crucial factors in the initiation of protective immunity against L. major infection, whereas T helper 2 cytokines including IL-5, IL-4, and IL-13 facilitate the persistence of parasites by downregulating the Th1 immune response. On the other hand, aggravation of inflammatory reactions leads to collateral tissue damage and formation of ulcer. For this reason, immunity system such as T regulatory cells produce regulatory cytokines such as transforming growth factor-β and IL-10 to inhibit possible injures caused by increased inflammatory responses in infection site. In this article, we review the role of pro- and anti-inflammatory cytokines in the immunoprotection and immunopathology of CL.

25 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GCGbd 2019 Snakebite Envenomation Collaborators
Gbd 2019 Snakebite Envenomation Collaborators
NRNicholas L. S. Roberts
Nicholas L. S. Roberts
EJEmily K. Johnson
Emily K. Johnson
SZScott M. Zeng
Scott M. Zeng
EHErin B. Hamilton
Erin B. Hamilton
KOKanyin Liane Ong
Kanyin Liane Ong
Snakebite envenoming is an important cause of preventable death. The World Health Organization (WHO) set a goal to halve snakebite mortality by 2030. We used verbal autopsy and vital registration data to model the proportion of venomous animal deaths due to snakes by location, age, year, and sex, and applied these proportions to venomous animal contact mortality estimates from the Global Burden of Disease 2019 study. In 2019, 63,400 people (95% uncertainty interval 38,900–78,600) died globally from snakebites, which was equal to an age-standardized mortality rate (ASMR) of 0.8 deaths (0.5–1.0) per 100,000 and represents a 36% (2–49) decrease in ASMR since 1990. India had the greatest number of deaths in 2019, equal to an ASMR of 4.0 per 100,000 (2.3—5.0). We forecast mortality will continue to decline, but not sufficiently to meet WHO’s goals. Improved data collection should be prioritized to help target interventions, improve burden estimation, and monitor progress.

23 August 2021 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
AAAmir Abdoli
Amir Abdoli
SFShahab Falahi
Shahab Falahi
AKAzra Kenarkoohi
Azra Kenarkoohi

1 July 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
MJMirza Ali Mofazzal Jahromi
Mirza Ali Mofazzal Jahromi
AAAmir Abdoli
Amir Abdoli
MRMohammad Rahmanian
Mohammad Rahmanian
HBHassan Bardania
Hassan Bardania
MBMehrdad Bayandori
Mehrdad Bayandori
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin

24 December 2019 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
FBFares Bahrami
Fares Bahrami
EBErfan Babaei
Erfan Babaei
ABAlireza Badirzadeh
Alireza Badirzadeh
TRTahereh Rezaei Riabi
Tahereh Rezaei Riabi
AAAmir Abdoli
Amir Abdoli